{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:42:43Z","timestamp":1780519363229,"version":"3.54.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grant INV-009333"],"award-info":[{"award-number":["Grant INV-009333"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Detection of poliovirus transmission and ongoing oral poliovirus vaccine (OPV) use continue to delay poliomyelitis eradication. In 2016, the Global Polio Eradication Initiative (GPEI) coordinated global cessation of type 2 OPV (OPV2) for preventive immunization and limited its use to emergency outbreak response. In 2019, GPEI partners requested restart of some Sabin OPV2 production and also accelerated the development of a genetically modified novel OPV2 vaccine (nOPV2) that promised greater genetic stability than monovalent Sabin OPV2 (mOPV2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed integrated risk, economic, and global poliovirus transmission modeling performed before OPV2 cessation, which recommended multiple risk management strategies to increase the chances of successfully ending all transmission of type 2 live polioviruses. Following OPV2 cessation, strategies implemented by countries and the GPEI deviated from model recommended risk management strategies. Complementing other modeling that explores prospective outbreak response options for improving outcomes for the current polio endgame trajectory, in this study we roll back the clock to 2017 and explore counterfactual trajectories that the polio endgame could have followed if GPEI had: (1) managed risks differently after OPV2 cessation and\/or (2) developed nOPV2 before and used it exclusively for outbreak response after OPV2 cessation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The implementation of the 2016 model-based recommended outbreak response strategies could have ended (and could still substantially improve the probability of ending) type 2 poliovirus transmission. Outbreak response performance observed since 2016 would not have been expected to achieve OPV2 cessation with high confidence, even with the availability of nOPV2 prior to the 2016 OPV2 cessation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>As implemented, the 2016 OPV2 cessation failed to stop type 2 transmission. While nOPV2 offers benefits of lower risk of seeding additional outbreaks, its reduced secondary spread relative to mOPV2 may imply relatively higher coverage needed for nOPV2 than mOPV2 to stop outbreaks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1098419","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:39:57Z","timestamp":1679632797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation"],"prefix":"10.3389","volume":"11","author":[{"given":"Kimberly M.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika A.","family":"Kalkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Badizadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0951-8320(99)00019-8","article-title":"Validating analytical judgments: the case of the airbag's lifesaving effectiveness","volume":"66","author":"Thompson","year":"1999","journal-title":"Reliability Eng Syst Safety."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100943","DOI":"10.1016\/j.accpm.2021.100943","article-title":"Anticipating COVID-19 intensive care unit capacity strain: A look back at epidemiological projections in France","volume":"40","author":"Sofonea","year":"2021","journal-title":"Anaesth Crit Care Pain Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000-2019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines."},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/risa.13484","article-title":"Reflections on modeling poliovirus transmission and the polio eradication endgame","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"B5","unstructured":"2023"},{"key":"B6","year":"1988","journal-title":"Global Eradication of Poliomyelitis by the Year 2000 (resolution 41.28)"},{"key":"B7","year":"1997","journal-title":"Global Eradication of Poliomyelitis: Report of the Second Meeting of the Global Technical Consultative Group (TCG)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Duintjer Tebbens","year":"2006","journal-title":"Risk Anal."},{"key":"B9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/risa.12022","article-title":"Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a009924","article-title":"Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative","volume":"150","author":"Fine","year":"1999","journal-title":"Am J Epidemiol."},{"key":"B11","year":"2008","journal-title":"Poliomyelitis: Mechanism for Management of Potential Risks to Eradication (resolution 61.1)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/erv.11.195","article-title":"Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation","volume":"11","author":"Thompson","year":"2012","journal-title":"Expert Rev Vaccines."},{"key":"B13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12879-015-1116-4","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/infdis\/jiac130","article-title":"Polio by the numbers-a global perspective","volume":"226","author":"Badizadegan","year":"2022","journal-title":"J Infect Dis."},{"key":"B15","unstructured":"2013"},{"key":"B16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1539-6924.2012.01891.x","article-title":"Modeling population immunity to support efforts to end the transmission of live polioviruses","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1093\/infdis\/jit838","article-title":"Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation","volume":"210","author":"Duintjer Tebbens","year":"2014","journal-title":"J Infect Dis."},{"key":"B19","first-page":"561","article-title":"Meeting of the strategic advisory group of experts on immunization, October 2014\u2014conclusions and recommendations","volume":"89","year":"2014","journal-title":"Weekly Epidemiol Record"},{"key":"B20","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine\u2014worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR."},{"key":"B21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infecti Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12879-015-1114-6","article-title":"Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12879-015-1112-8","article-title":"An economic analysis of poliovirus risk management policy options for 2013\u20132052","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12879-015-1115-5","article-title":"Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2217\/fmb-2016-0126","article-title":"The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management","volume":"11","author":"Duintjer Tebbens","year":"2016","journal-title":"Future Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4172\/2157-7560.1000339","article-title":"Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management","volume":"7","author":"Duintjer Tebbens","year":"2016","journal-title":"J Vaccines Vacc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: updated integrated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"B28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"B29","doi-asserted-by":"publisher","first-page":"S0264","DOI":"10.1016\/j.vaccine.2022.02.050.","article-title":"Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel oral polio vaccine type 2 (nOPV2) experience","author":"Macklin","year":"2022","journal-title":"Vaccine"},{"key":"B30","unstructured":"2015"},{"key":"B31","unstructured":"2016"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/infdis\/jix128","article-title":"Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","article-title":"Poliovirus vaccination during the endgame: Insights from integrated modeling","volume":"16","author":"Duintjer Tebbens","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1093\/infdis\/jix108","article-title":"Lessons from the polio endgame: Overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2381468317697002","DOI":"10.1177\/2381468317697002","article-title":"Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use","volume":"2","author":"Duintjer Tebbens","year":"2017","journal-title":"Med Decis Making Policy Practice."},{"key":"B38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/sdr.1589","article-title":"Using integrated modeling to support the global eradication of vaccine-preventable diseases","volume":"34","author":"Duintjer Tebbens","year":"2018","journal-title":"System Dyn Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1017\/S095026881900181X","article-title":"Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters","volume":"147","author":"Kalkowska","year":"2019","journal-title":"Epidemiol Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fvl-2018-0079","article-title":"Poliovirus containment risks and their management","volume":"13","author":"Duintjer Tebbens","year":"2018","journal-title":"Future Virol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/14760584.2019.1635463","article-title":"Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)","volume":"18","author":"Thompson","year":"2019","journal-title":"Expert Rev Vaccines."},{"key":"B42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science."},{"key":"B43","unstructured":"2019"},{"key":"B44","year":"2020","journal-title":"Global Polio Eradication Initiative. Strategy For The Response To Type 2 Circulating Vaccine-Derived Poliovirus 2020\u20132021: Addendum To The Polio Eradication And Endgame Strategy 2019\u20132023"},{"key":"B45","unstructured":"2021"},{"key":"B46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of poliovirus outbreak response strategies for 2019\u20132029: impacts of the use of novel OPV2 strains","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S0264","DOI":"10.1016\/j.vaccine.2021.04.026.","article-title":"The impact of disruptions caused by the COVID-19 pandemic on global polio eradication","author":"Kalkowska","year":"2021","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S0264","DOI":"10.1016\/j.vaccine.2021.04.061.","article-title":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","author":"Kalkowska","year":"2021","journal-title":"Vaccine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S0264","DOI":"10.1016\/j.vaccine.2022.10.060.","article-title":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","author":"Kalkowska","year":"2022","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Konopka-Anstadt","year":"2020","journal-title":"NPJ Vaccines."},{"key":"B51","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/risa.12044","article-title":"Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1264","DOI":"10.1016\/S2214-109X(20)30308-9","article-title":"Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits vs. excess risk of SARS-CoV-2 infection","volume":"8","author":"Abbas","year":"2020","journal-title":"Lancet Global Health."},{"key":"B53","doi-asserted-by":"publisher","first-page":"786","DOI":"10.15585\/mmwr.mm7124a2","article-title":"Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing\u2014worldwide, March\u2013October 2021","volume":"71","author":"Martin","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-015-1113-7","article-title":"Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B55","unstructured":"2023"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1098419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:40:02Z","timestamp":1679632802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1098419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":55,"alternative-id":["10.3389\/fpubh.2023.1098419"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1098419","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"article-number":"1098419"}}